HighTower Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

HighTower Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24	Closed	-$8.44K	–	3821
2023 Q3	$8.44K	Buy	+24	New	+$289	﹤0.01%	3399

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's RIGL Position: Q1 2026 in Review

HighTower Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 11,088 shares — an estimated $475K sold.

HighTower Advisors first reported a position in RIGL in Q2 2013 and held it in 33 quarters. The position peaked at $475K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

HighTower Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 11,088 Rigel Pharmaceuticals shares in Q1 2026, an estimated $475K.
HighTower Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 33 quarters.
HighTower Advisors's Rigel Pharmaceuticals position peaked at $475K in Q4 2025.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.